GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tanvex BioPharma Inc (TPE:6541) » Definitions » Capex-to-Revenue

Tanvex BioPharma (TPE:6541) Capex-to-Revenue : 11.62 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Tanvex BioPharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Tanvex BioPharma's Capital Expenditure for the three months ended in Dec. 2024 was NT$-32.66 Mil. Its Revenue for the three months ended in Dec. 2024 was NT$2.81 Mil.

Hence, Tanvex BioPharma's Capex-to-Revenue for the three months ended in Dec. 2024 was 11.62.


Tanvex BioPharma Capex-to-Revenue Historical Data

The historical data trend for Tanvex BioPharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tanvex BioPharma Capex-to-Revenue Chart

Tanvex BioPharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 224.98 5.61 4.29 1.16 3.19

Tanvex BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.29 10.63 1.82 0.99 11.62

Competitive Comparison of Tanvex BioPharma's Capex-to-Revenue

For the Biotechnology subindustry, Tanvex BioPharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tanvex BioPharma's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's Capex-to-Revenue falls into.



Tanvex BioPharma Capex-to-Revenue Calculation

Tanvex BioPharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-110.768) / 34.678
=3.19

Tanvex BioPharma's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-32.657) / 2.81
=11.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tanvex BioPharma  (TPE:6541) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Tanvex BioPharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tanvex BioPharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tanvex BioPharma Business Description

Traded in Other Exchanges
N/A
Address
No. 376, Ren'ai Road, Section 4, 13th Floor-1, Da'an District, Taipei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States.

Tanvex BioPharma Headlines

No Headlines